Association of Interleukin–18 with Sustained Virological Response (SVR) To Interferon Therapy in Patients with Chronic Liver Diseases
نویسندگان
چکیده
Background: Pegylated interferon plus ribavirin is the standard therapy for treatment of Chronic hepatitis C (CHC) patients, this therapy is only effective in 50–60% of infected individuals. Pretreatment predictors associated with sustained virological response (SVR) to interferon treatment have not yet been fully investigated. Several factors have been shown to influence response to antiviral treatment, one of them is interleukin – 18 (IL18). There are few data on IL-18 in relation to infectious diseases, but it plays a prominent role in chronic HCV infection. Thus, the current study is designated to assess serum Interleukin – 18 levels in CHC genotype 4 patients and its association with treatment response. Patients and Methods: This study was performed on fifty Egyptian chronic hepatitis C patients, who received combined pegylated interferon alpha and ribavirin therapy and twenty healthy blood donors as a control group. Quantitative hepatitis C virus RNA was done by real time RT-PCR technique. Serum IL-18 level was assayed using quantitative ELISA plate method. Results: The mean level of IL18 was significantly higher in CHC patients (212.15 Pg/ml) compared to the controls (48.95 Pg/ml). IL-18 level in responders was significantly reduced after 6 months from the end of treatment compared to those at baseline level (P=0.001), but such decrease was lower than that in non responders (P=0.058). IL-18 level was positively correlated with high and moderate viral load in non responders. Conclusions: Serum IL18 level has the potential to be used as a biological marker to predict outcome of antiviral therapy among CHC genotype 4 patients. [Waleed S. Mohamed, Samah A. Loutfy, Amal A. Mohamed and Marwa Amer. Association of Interleukin–18 with Sustained Virological Response (SVR) To Interferon Therapy in Patients with Chronic Liver Diseases. Life Sci J 2012;9(4):4542-4550]. (ISSN: 1097-8135). http://www.lifesciencesite.com. 681
منابع مشابه
Factors influencing therapeutic response to peginterferron plus ribavirin in the different genotypes of chronic hepatitis C
Abstract Background: Different factors like age, sex, route of infection, initial viral load, levels of liver function tests and genotypes may affect response to treatment in patients with chronic hepatitis C. The purpose of this study was to determine the role of these factors in the treatment of these patients. Methods: From 2004 to 2012, different genotypes of chronic HCV (Hepatitis C ...
متن کاملSafety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...
متن کاملPolymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin
Background: Nowadays, the immune response to hepatitis C (HCV) treatment has become a crucial issue mostly due to the interleukin 28B (IL-28B) polymorphism effects in chronic HCV patients. The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin. Methods...
متن کاملمقایسه پاسخ درمانی مداوم بیماران مبتلا به هپاتیت مزمن C با رژیم اینترفرون معمولی در مقابل پگیلیتد اینترفرون
Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...
متن کاملEFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کامل